Purpose: This study assessed the safety/tolerability, pharmacokinetics, and clinical activity of three times weekly i.v. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with once-weekly i.v. cisplatin and daily pelvic radiation in patients with gynecologic malignancies. 3-AP is a novel small-molecule inhibitor of ribonucleotide reductase (RNR) and is being tested as a potential radiosensitizer and chemosensitizer.
Single-and double-strand DNA breaks resulting from therapeutic ionizing radiation (IR) and replication fork blocks caused by cisplatin-induced DNA adduct formation must be effectively repaired for cell survival and replication. The rate-limiting step in the de novo synthesis of deoxyribonucleotide triphosphate, which is critical for DNA damage repair, is catalyzed by ribonucleotide reductase (RNR). RNR has two constitutively expressed homodimeric active-site subunits (RNR-M1) and two tightly regulated homodimeric small subunits (RNR-R2 or p53R2) that carry diferric irons stabilizing a tyrosyl free radical that is critical for catalytic function (1, 2) . RNR activity correlates with tumor proliferation rate and repair of IR-induced DNA damage (3) (4) (5) (6) . Inhibiting RNR activity is not a new approach, as one of the earliest cervical cancer clinical trials targeted RNR with the chemotherapeutic hydroxyurea. The Gynecologic Oncology Group showed significant improvement in response (68% versus 49%), disease-free survival (13.6 versus 7.6 mo), and median survival (19.5 versus 10.7 mo) with hydroxyurea-radiation versus radiation treatment (7) . Leukopenia became a dose-limiting toxicity (DLT) of oral daily hydroxyurea (8) (9) (10) (11) .
The investigational chemotherapeutic drug 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine, NSC#663249) is a 1,000-fold more potent irreversible inhibitor of the RNR-R2 and p53R2 subunits of RNR as compared with hydroxyurea (11) (12) (13) . Preclinical studies have shown that 3-AP suppresses deoxyribonucleotide triphosphate generation required for IR-related DNA damage repair and thereby enhances IR cytotoxicity (14) (15) (16) . Moreover, cervical cancer cells show a 17-fold increase in RNR-R2 protein and a 4-fold increase in RNR activity 18 to 24 hours after IR (5) , suggesting that therapeutic RNR targeting may affect cervical cancer treatment. Our in vitro data show that cervical cancer cells exposed to IR plus 3-AP experience a G 1 cell cycle block and increased IR cytotoxicty (16) . Given these findings, RNR inhibition following radiation is an appealing therapeutic strategy.
In phase I solid cancer studies, single agent 3-AP was well tolerated at doses of 96 to 100 mg/m 2 (17) (18) (19) . Pharmacokinetic data indicate that 3-AP concentrations peak at 1 to 10 μmol/L at 1 to 2 hours after a 2-hour i.v. infusion. In another phase I solid cancer study, 2-hour 96 mg/m 2 i.v. 3-AP (days 1-5) plus 25 or 37.5 mg/m 2 i.v. cisplatin (day 2 or day 3) given every other week or every 3 weeks showed a pooled 33% clinical response rate (20) . Thus, 3-AP also seems to modify cisplatin-mediated cytotoxicity.
This study was designed to (a) assess the safety/tolerability of a three times weekly 2-hour i.v. 3-AP infusion during daily pelvic radiation and weekly i.v. cisplatin chemotherapy; (b) assess the 2-hour 3-AP infusion pharmacokinetics during radiation and cisplatin treatment; (c) evaluate methemoglobin levels and cancer tissue RNR activity as markers of 3-AP pharmacologic inhibition; and (d) assess the clinical activity of radiation and cisplatin plus 3-AP chemotherapy.
Patients and Methods
Eligibility criteria. Enrolled patients were females of ages ≥18 y with histologically confirmed primary or recurrent gynecologic malignancies not amenable to curative surgery. Patients had a Karnofsky performance status of ≥50%; life expectancy of ≥12 wk; hemoglobin concentration ≥10 g/dL, absolute granulocyte count ≥1,500/μL, platelet count ≥100,000/μL, total bilirubin ≤2.0 mg/dL, aspartate aminotransferase/alanine aminotransferase ≤2.5× and prothrombin time/activated partial thromboplastin time ≤1.5 × institutional normal limits, and plasma creatinine ≤2.0 mg/dL. Previously treated patients were off therapy for 4 wk. Patients with symptomatic cardiac and/or pulmonary disease were excluded.
The study protocol was approved by the National Cancer Institute (NCI) Cancer Therapeutics Evaluation Treatment (CTEP) committee and the institutional review board of University Hospitals of Cleveland Case Medical Center and monitored by the Case Comprehensive Cancer Center Data Safety and Monitoring Board. All patients provided a signed informed consent.
Safety assessments. Patients underwent examination and hematologic, hepatic, and renal blood testing and baseline computed tomography (CT) or 2-[
18 F]fluoro-2-deoxy-Dglucose positron emission tomography scans ([ 18 F]FDG PET/CT) within 28 d before the first 3-AP infusion. Physical examinations, adverse event assessments (NCI Common Toxicity Criteria version 3.0), and bloodwork were repeated weekly. Post-study examinations and adverse event assessments were required at 1 and 3 mo after completing all radiation. Patients were followed every 3 mo thereafter. Optional 3-mo post-study [ 18 F]FDG PET/CT studies were recommended.
Protocol treatments. This was a dose-finding phase I study of three times weekly i.v. 3-AP (Triapine) in combination with once-weekly i.v. cisplatin chemotherapy and daily pelvic radiation therapy administered for 5 weekly cycles. 3-AP was supplied by Vion Pharmaceuticals to NCI-CTEP in 50-mg viscous liquid vials and, for 2-h i.v. infusion, was diluted in 0.9% sodium chloride to a final concentration of 0.01 to 2 mg/mL. A Fibonacci 3+3 cohort trial design was implemented for 2-h i.v. 3-AP dose escalation levels of 25, 50, 75, and 100 mg/m 2 . A single observed DLT event led to an additional three patients treated at the dose level where the DLT event occurred. Dose-finding escalation continued if no additional DLTs were observed. Two observed DLTs stopped dose escalation, with the prior dose level declared the maximum tolerated dose as long as six patients had been treated with ≤1 instance of DLT.
Cisplatin (40 mg/m 2 ) was given i.v. before radiation therapy once every week for 5 wk with an optional week 6 dosing. Cisplatin and 3-AP were not given on the same day.
Pelvic radiation consisted of parallel-opposed anteroposterior-posterioranterior and lateral pelvic externalbeam treatment fields, delivering 25 fractions of 1.8-Gy daily fractions for a total dose of 45.0 Gy using 6-to 18-MV photons (Table 1 ). An optional parametrial boost (n = 10) of 5 fractions of 1.8-Gy daily fractions for a total dose of 9.0 Gy was administered using parallel-opposed anteroposterior-posterioranterior fields. Brachytherapy in patients with cervical cancer (n = 10) followed pelvic radiation such that total radiation treatment time was less
Translational Relevance
Worldwide, half a million women are diagnosed annually with cervical cancer, with 90% of new cervical cancer cases related to human papillomavirus-silenced p53. Cancer cell replication depends on ribonucleotide reductase (RNR), the rate-limiting enzyme catalyzing de novo deoxyribonucleotide production needed for DNA synthesis. After ionizing radiation, RNR activity increases, facilitating DNA repair and decreasing cancer cell sensitivity to this important cancer treatment. A new intravenous and oral antitumor drug, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), potently inhibits RNR. In this study, we report the National Cancer Institute-Cancer Therapeutics Evaluation Treatment sponsored phase I safety and translational science clinical trial of radiation and cisplatin plus 3-AP in patients with locally advanced stage IB2 to IVa cervical cancer. In this 10-patient study population at high-risk for relapse and cancer-related death, a 100% complete response rate was observed and no disease progression was documented through 18 months of median follow-up. than 56 d. Intracavitary (n = 9) or interstitial (n = 1) lowdose rate brachytherapy was allowed. Brachytherapy treatment increased total point A dose to a median 80.0 Gy (median 43 h; median 62 cGy/h). No cisplatin or 3-AP infusions were given during brachytherapy.
3-AP plasma pharmacokinetic and serum methemoglobin measurements. Heparinized intravenous blood samples determined 3-AP concentrations on day 1 and day 10 before and at 2, 4, 6, and 24 h after start of 2-h infusion. Plasma was centrifuged at 3,000 rpm (15 min) in a refrigerated centrifuge and then stored (−80°C). 3-AP concentrations were measured by liquid chromatography tandem mass spectrometry, as previously described (21) . The lower limit of quantification was 20 ng/mL. Median peak plasma concentrations (C max ) and terminal elimination constants for drug half-life were calculated by noncompartmental methods (SPSS 12.0).
Heparinized intravenous blood samples drawn into arterial blood gas syringes determined serum methemoglobin concentrations on day 1 and day 10 before and at 2, 4, 6, and 24 h after start of 2-h infusion. Methemoglobin levels were reported as a percentage of total hemoglobin observed by direct spectrophotometry (22, 23) .
Sequential tumor biopsies, immunohistochemistry, and RNR assay. Tumor biopsies were obtained before radiation plus 3-AP (day 1) and again on day 10 by transvaginal punch biopsy (∼500 mg, 0.5 cm 3 ), then snap-frozen (<30 min) and stored (−80°C). For immunohistochemistry, the distal 0.5-mm biopsy ends were sectioned and stained with H&E to confirm presence of tumor (24) . Modified immunohistochemistry assays were done using RNR-R2 mouse monoclonal (0.5 mg/mL, 1:100; Abcam, Inc.) and RNR-p53R2 rabbit polyclonal (0.2 mg/mL, 1:250; Novus Biologicals) antibodies (25) . Adapting previous methods and blinded to treatment and response (26) , two pathologists scored immunohistochemistry specimens for RNR-R2 and p53R2 protein positivity: negative 0 (<5%), positive 1+ (5% to <25%), positive 2+ (25% to <75%), and positive 3+ (≥75%).
Tumor and stromal intracellular dCTP pools were quantified for RNR activity using a DNA polymerase extension assay (16) . Tumor biopsies were thawed and homogenized by glass microbead pulverization, and intracellular deoxyribonucleotide triphosphates were extracted by ice-cold 60% methanol. The DNA polymerase extension assay template was 5′-AAAGAAAGAAAGAAA-GAAAGGGCGGTGGAGGCGG-3′ and the primer was 5′-CCGCCTCCACCGCC-3′ (Integrated DNA Technologies). A liquid scintillation counter quantified radioactivity, with incorporated [ 3 H]dTTP radioactivity linearly proportional to dCTP (nmol/L/mg).
Evaluation of clinical activity and statistical methods. The study design reflected the desire to detect differential tumor response for translational biology end points (immunohistochemistry and RNR activity, day 1 and day 10) before any planned brachytherapy (i.e., after 5 wk of pelvic radiation and cisplatin plus 3-AP chemotherapy), even though complete study treatment concluded after brachytherapy. Thus, differences in tumor response could be compared among treated patients who did or did not receive brachytherapy. Early complete responders were defined as having disappearance of all active cancer after 5 wk of protocol therapy and before any brachytherapy. Late complete responders were defined as having disappearance of all active cancer after all protocol therapy and at the 1-mo follow-up assessment. Tumor response was reassessed following all protocol therapy at 1 mo by physical examination and at 3 mo by physical examination and repeat CT or [
18 F]FDG PET/CT imaging. Patients were followed every 3 mo. T tests, ANOVA, and Wilcoxon rank sum statistics (α = 0.05) were computed (SPSS 12.0). 
Results
leukocytopenia resulting in two delays of cisplatin administration. One patient, who had 9-cm abdominopelvic relapse of her uterine stromal sarcoma, received a single 50 mg/m 2 3-AP infusion and four pelvic radiation doses for abdominopelvic disease before symptomatic metastatic pulmonary disease progression.
Eighteen 3-AP drug-related adverse events occurred in 4 of 11 (36%) patients (Table 2) . Most 3-AP drug-related adverse events (14 of 18) were mild to moderate in intensity (i.e., grade ≤3, resolving to grade 0-2 within 2 days). The four DLTs occurred in two patients. One patient at the 50 mg/m 2 3-AP dose level had grade 3 anorexia requiring hospitalization; her anorexia resolved within 4 days. The other patient enrolled at the 50 mg/m 2 3-AP dose level had grade 3 nausea and dehydration requiring hospitalization for i.v. hydration, with a grade 3 increase in blood urea nitrogen, a grade 4 lowering of serum bicarbonate, and a grade 4 increase in serum creatinine observed and attributed to cisplatin administration. Grade 4 serum bicarbonate corrected to grade 2 after 2 days and grade 3 blood urea nitrogen and grade 4 creatinine corrected to grade 2 after 8 days of i.v. hydration in this one diabetic patient.
No significant 3-AP drug-related symptomatic dyspnea or methemoglobinemia was reported in the 10 cervical cancer patients. The one uterine sarcoma patient who had pulmonary metastases and prior chemotherapy experienced grade 3 hypoxia with peak methemoglobin level of 11% requiring continuous oxygen supplementation 4 hours after her first 50 mg/m 2 3-AP 2-hour infusion. After 24-hour continuous oxygen supplementation, her roomair oxygen saturation normalized and methemoglobin levels lowered to 1%.
Clinical activity. Ten of 11 (91%) enrolled patients were assessed for tumor response, each with squamous cervical cancer. All 10 (100%) patients achieved a complete clinical response at post-treatment 1-month follow-up. Of the 10 complete responders, 6 (60%) had an early complete clinical response (i.e., no disease detected after 5 weeks of radiation and cisplatin plus 3-AP chemotherapy). These six patients had a median tumor size of 7.5 cm (range 4-8 cm). The four late complete responders had a 7-cm (range 6-8 cm) median tumor size, which decreased to a 1-cm (range 1-1.5 cm) median after 5 weeks of radiation and cisplatin plus 3-AP chemotherapy. One late complete responder had a solitary pulmonary lesion at clinical presentation, achieved complete response of her pelvic cervical cancer following all protocol therapy, and had biopsy-confirmed nonviable pulmonary metastatic disease 2 months after completing cisplatin plus 3-AP chemotherapy. With a median follow-up of 18 months (range 6-32 months), the 10 evaluable patients had no disease progression. Five of these 10 patients had [ 18 F]FDG PET/CT metabolically avid pelvic or lower (L4-L5) para-aortic lymphadenopathy before treatment; none had disease relapse as assessed by repeat CT or [ 18 F]FDG PET/CT imaging.
Tumor tissue RNR protein levels and activity. One objective of the study was to identify, using immunohistochemistry and biochemical assays, biomarkers of the targeted enzyme RNR from day 1 and day 10 tumor biopsies that might distinguish responders from nonresponders. Figure  2 shows representative immunohistochemistry tumor biopsies from day 1 (pretreatment) and day 10 in early and late complete response cervical cancer patients. p53R2 and RMR-R2 protein expression levels by immunohistochemistry on day 1 and day 10 increased in six early complete responders (Fig. 2A) . Four late complete responders exhibited unchanged, elevated day 1 and day 10 p53R2 and RNR-R2 protein levels (Fig. 2B) . Figure 3 shows RNR activity using a biochemical assay from cervical cancer biopsies expressed as a ratio of day 10 to day 1 and correlated with treatment response. Our recent in vitro data suggest that radiation treatment significantly increases RNR activity, whereas radiation plus 3-AP treatment significantly reduces RNR activity (16) . Among six early complete responders, radiation and cisplatin plus 3-AP chemotherapy resulted in no substantial change in RNR activity ratio for day 1 versus day 10, ranging between 0.37 and 1.30 (Fig. 3) . Among four late complete responders, day 10 RNR activity levels were substantially higher than day 1, with ratios ranging between 2.15 and 9.55 (P = Fig. 1 . Phase I clinical trial schema. E, enrollment; qwk, per week; PK, pharmacokinetic sampling; MetHgb, methemoglobin sampling; Tumor Bx, transvaginal tumor biopsy; FU, after all protocol therapy completion follow-up; CRA, clinical response assessment. 0.02; Fig. 3 ). On average, the four late complete responders showed a 2.5-fold elevation in dCTP pool levels on day 10. The patient that had the highest RNR activity day 10/day 1 ratio (i.e., 9.55) had a clinical 8-cm tumor shrink to 2 cm after 5 weeks of radiation and cisplatin plus 3-AP chemotherapy; the patient then achieved a late complete response after all protocol therapy including brachytherapy.
Pharmacokinetics and methemoglobin levels. Median (i.e., both day 1 and day 10) 3-AP plasma concentration profiles are shown in Fig. 4 (bottom) . Plasma concentrations reached C max at the completion of a 2-hour 3-AP infusion, with median peak plasma concentrations of 277 ng/mL (25 mg/m 2 ) and 467 ng/mL (50 mg/m 2 ) and a half-life of 2 hours with no change in day 1 and day 10 levels (25 mg/m 2 , P = 0.18; 50 mg/m 2 , P = 0.35). 3-AP plasma concentrations, on average, decayed to 2% (25 mg/m 2 ) and 13% (50 mg/m 2 ) of observed C max at 6 hours after start of 2-hour infusion.
Median (i.e., both day 1 and day 10) methemoglobin percentages are shown in Fig. 4 (top) . 3-AP is an iron chelator that is able to inhibit iron-dependent cytochrome b 5 and methemoglobin reductases in RBC (12) . Pharmacologic inhibition of RBC reductases leads to an accumulation of ferric (III) methemoglobin through naturally occurring, spontaneous oxidation of RBC ferrous (II) hemoglobin (27) . Methemoglobin is incapable of binding oxygen and manifests biologically as tissue hypoxia and clinically as dyspnea. In a prior phase I clinical trial, every-4-week infusion of 3-AP (105 mg/m 2 , day 1) plus gemcitabine (600-1,000 mg/m 2 , days 1, 8, and 15) resulted in dose-limiting, symptomatic methemoglobinemia (>10% MHgb) in 3 of 29 (10%) patients (28) . In this study, median peak methemoglobin was 1% (range 0-2%) for the 25 mg/m 2 and 6% (range 1-11%) for the 50 mg/m 2 dosing 4 hours after start of 2-hour 3-AP infusion (P < 0.001), with no difference between day 1 and day 10 (P = 1.00). parametrial tissue or pelvic wall muscle invasion and nephropathy. Early complete clinical responses were achieved in 6 of 10 (60%) patients after 5 weeks of daily pelvic radiation and cisplatin plus 3-AP chemotherapy and before intracavitary brachytherapy. At 1 and 3 months after completing all protocol therapy including brachytherapy, all 10 (100%) cervical cancer patients achieved complete tumor response. With a median 18 months of follow-up (range 6-32 months), there has been no documented local or distant disease relapse. Historically, pelvic radiation plus cisplatin chemotherapy followed by brachytherapy achieves a 70% complete clinical response and a 73% 18-month progression-free survival in advanced stage cervical cancer patients (29) (30) (31) .
Here, 3-AP pharmacokinetics did not display a timedependent increase in the 24-hour pharmacokinetic evaluations done on both day 1 and day 10 and no corresponding symptomatic increase in serum methemoglobin. As such, 3-AP treatment was scheduled three times weekly to provide repeated drug-induced RNR inhibition and, thereby, prolonged inhibition of on-demand deoxyribonucleotide synthesis during radiation. We observed 3-AP drug concentrations sufficient to achieve tumor responses up to 4 hours post-dose (Fig. 4) , and as such, frequent 3-AP dosing seems reasonable for 3-AP-mediated radiosensitization. Using experimental cervical cancer cell models, we found that 3-AP treatment significantly enhanced IR-related cytotoxicity through a significant 3-AP-induced reduction in RNR activity, sustained IRinduced DNA damage, and a long G 1 -phase cell cycle arrest perhaps indicating a p53-independent radiosensitizing mechanism (16). . Histopathology (H&E) shows high-grade cervical cancer with evident radiation-drug treatment effect comparing biopsy specimens pretreatment (day 1) to on-treatment (day 10) sections. Immunohistochemical staining shows increase in pretreatment day 1 to day 10 RNR-R2 and p53R2 protein levels in an early complete response patient (A) but unchanged elevated RNR-R2 and p53R2 protein levels in a late complete response patient (B).
In this clinical trial, we measured the target enzyme RNR in day 1 and day 10 tumor biopsies using two different assays: an immunohistochemistry assay of RNR-R2 and RNR p53R2 protein expression levels and a biochemical assay of total RNR activity. Based on this small patient series, an early complete response (six patients) was associated with a moderate change in the immunohistochemistry assay (Fig. 2) and no change in the biochemical assay (Fig. 3) comparing day 1 to day 10 cancer biopsies. In early complete responders in whom low pretreatment RNR-R2 and RNR-p53R2 protein levels were observed, it can be argued that 3-AP treatment effectively reduced a predictably higher RNR activity level in these cervical cancers, based on our prior in vitro data, resulting in no change in the RNR biochemical assay (5, 6, 16) . In late complete responders in whom we found no change in the elevated RNR-R2 and RNR-p53R2 protein levels by immunohistochemistry, comparing pretherapy (day 1) to on-therapy (day 10) tumor biopsy sections (Fig. 2) and actually higher RNR activity levels (Fig. 3) , one could argue that the overall effect of 3-AP treatment was less than optimal. However, these late complete responders have experienced durable responses with a median follow-up of 18 months similar to early complete responders, suggesting that additional 3-AP mechanisms of radiosensitization and chemosensitization are operative. As discussed in detail in our recent publication, multiple mechanisms of radiosensitization by 3-AP may contribute to the overall tumor cytotoxicity, including an enhanced G 1 -S cell cycle delay and reduced radiation-mediated DNA damage repair. Enhanced tumor cytotoxicity in these patients could also result from IR-cisplatin interactions independent of 3-AP treatment.
Durable clinical activity was observed with a median 18-month follow-up after administering i.v. 25 mg/m 2 3-AP doses given three times weekly during pelvic radiation and cisplatin chemotherapy in advanced stage cervical cancer patients. The favorable adverse event profile of this combination makes this regimen an exciting new cervical cancer treatment for women. A confirmatory phase II study of daily pelvic radiation and once-weekly cisplatin 
Disclosure of Potential Conflicts of Interest
There are no potential conflicts of interest among the authors of this article. This article has been seen, read, and agreed on in its content by all designated authors. This article has not been submitted or published elsewhere.
